Thursday, 21 Mar 2019

You are here

Allopurinol Shown to be Renal Protective

Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.

Historically, it has been claimed that allopurinol should be dose-adjusted in patients with renal insufficiency, implying that the drug may lend to renal impairment in susceptible individuals.

Researchers used a UK population for a prospective cohort study of newly diagnosed gout patients initiating allopurinol (≥300 mg/d) compared to those who did not initiate allopurinol. Thus, adults with newly diagnosed gout were propensity matched: 4760 initiators of allopurinol (≥300 mg/d) vs. the same number of noninitiators of allopurinol. Patients with chronic kidney disease stage 3 or higher or prior urate-lowering therapy were excluded.

Patients had a mean follow-up time of 4-5 years, mean age of 57 years, and mean body mass index 30.

Amongst these patients, chronic kidney disease stage 3 or higher was seen in 11.1% of allopurinol initiators and 13.1% of non-users.

Allopurinol (≥300 mg/d) was associated with a 13% lower risk of developing developing chronic kidney disease stage 3 or higher compared with nonusers (hazard ratio (HR) 0.87; 95% CI, 0.77-0.97).  Doses lower than 300 mg/d were not associated with protection against stage >3 CKD (HR, 1.00; 95% CI, 0.91-1.09).

Allopurinol dosed at 300 mg/d or higher was associated with a lower risk of renal function deterioration. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Ironwood Retreats from the US Gout Market

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.

The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.

Allopurinol Reduces Cardiovascular Outcomes in Diabetes

A Canadian study has shown that elderly diabetics who take allopurinol have a significant reduction in cardiovascular outcomes.  

Hyperuricemia has been shown to be a biomarker for cardiovascular outcomes in multiple disorders. These investigators studied the effect of allopurinol and mortality on CV outcomes in a population-based retrospective cohort study from Ontario, Canada.

FDA Slaps a Boxed Warning on Febuxostat for CV Risk

The U.S. Food and Drug Administration (FDA) has reviewed data from the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial and concluded there is an increased risk of death with Uloric (febuxostat) compared with allopurinol, and has added this as a boxed warning to the drug’s product label.

U.S. Gout Rates Remain Steady, but Substantial

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.

Febuxostat Gets Reprieve from FDA Advisory Panel

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study. 

The Vote